Healthcare / Medical DevicesStockholm
$509.00
-20.00 (-3.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $280.5M · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.6B
P/E
34.0x
↑EV/EBITDA
16.4x
↑ROE
15.1%
↑Gross Margin
58.6%
↑Debt/Equity
0.33
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+23.8%
FCF CAGR
+89.5%
FCF margin
13.3%
FCF / Net income
1.28x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.11B · net income $219.8M · FCF $280.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.11B | $2.11B | $1.81B | $1.59B | $1.11B |
| Net Income | $219.8M | $219.8M | $207.4M | $172.2M | $117.6M |
| EBITDA | $473.8M | $473.8M | $395.5M | $341.9M | $256.2M |
| EPS | 14.70 | 14.70 | 14.00 | 11.60 | 7.90 |
| Gross Margin | 58.6% | 58.6% | 58.5% | 58.4% | 60.9% |
| Operating Margin | 13.7% | 13.7% | 13.3% | 13.6% | 13.4% |
| Net Margin | 10.4% | 10.4% | 11.5% | 10.8% | 10.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.33 | 0.33 | 0.28 | 0.26 | 0.40 |
| Current Ratio | 2.10 | 2.10 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $280.5M | $280.5M | $293.7M | $188.7M | $41.2M |
| Returns | |||||
| ROE | 15.1% | 15.1% | 16.2% | 16.8% | 13.7% |
| Valuation | |||||
| P/E | 33.96 | 33.96 | 43.43 | 27.63 | 26.39 |
| EV/EBITDA | 16.36 | 16.36 | 22.82 | 14.14 | 12.46 |
| P/B | 5.26 | 5.26 | 7.05 | 4.65 | 3.61 |
| Growth & Yield | |||||
| Revenue Growth | 16.7% | 16.7% | 13.8% | 42.8% | — |
| EPS Growth | 5.0% | 5.0% | 20.7% | 46.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
45.4%
EPS terminal req.
$45.17
Spread vs growth
-40.4%
5Y implied EPS CAGR
30.0%
EPS terminal req.
$54.65
Spread vs growth
-25.0%
10Y implied EPS CAGR
19.6%
EPS terminal req.
$88.01
Spread vs growth
-14.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.5%
Start / end P/E
31.8x → 34.7x
EPS bridge
14.00 → 14.70
Residual
+0.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.